TOFA and Weight Loss: What the New Fat-Loss and Muscle-Preservation Research Actually Shows
A decades-old research compound called TOFA is suddenly in the weight-loss conversation because obese mice lost substantial body weight without eating less—and most of the measured change came from fat while lean mass was largely preserved. That is more scientifically interesting than another headline about a compound making the scale move.
The 2026 study, published in Science Advances by a UC Berkeley-led research team, suggests that 5-tetradecyloxy-2-furoic acid may increase energy expenditure while changing how cells make and use fat. In separate mouse experiments, TOFA also produced stronger metabolic effects when combined with semaglutide or tirzepatide.
This remains preclinical obesity research. TOFA is not an approved human weight-loss medication. There are no human obesity trials establishing systemic safety, effective dosing, weight-loss efficacy, or long-term outcomes. A topical prodrug of TOFA was studied years ago for acne, but that does not establish that oral or systemic TOFA is safe for treating obesity.
Forge Verdict
The TOFA research is genuinely interesting because researchers produced substantial fat loss in obese male mice without reducing food intake and without a statistically significant loss of lean mass. It points toward a different possible way of treating obesity—one aimed more at energy expenditure and lipid metabolism—and the combination experiments raise the possibility that this type of approach could eventually complement incretin medications. But this is still animal research. It should not be interpreted as evidence that TOFA is a safe or effective human weight-loss drug.
Roughly 18% Lower
In a key diet-induced obesity experiment, TOFA produced a large reduction in body weight over approximately four weeks.
No Significant Reduction
The animals did not appear to lose weight because they were simply eating less.
Fat Down, Lean Mass Largely Preserved
EchoMRI showed a significant reduction in fat mass without a statistically significant decline in lean mass.
What Is TOFA?
TOFA stands for 5-tetradecyloxy-2-furoic acid. It is not a newly invented molecule designed to compete with Ozempic, Wegovy, Zepbound, or Mounjaro. TOFA was synthesized decades ago and became known as a research compound that interferes with fatty-acid synthesis.
The 2026 paper reframed the molecule because the researchers found evidence that TOFA does more than inhibit acetyl-CoA carboxylase enzymes, or ACC1 and ACC2. They also found that TOFA directly binds to and partially activates two nuclear receptors called PPARα and PPARδ.
In plain English, TOFA appears to push metabolism in two related directions at once: make less new fat and increase the machinery involved in using fat for energy.
That dual activity may matter. When the researchers tried to reproduce the effect using a separate ACC inhibitor plus a separate PPAR-targeting compound, the combination did not fully reproduce TOFA's overall metabolic effects. The research team believes having both activities inside one molecule may create a coordinated response that is different from simply stacking two unrelated drugs.
TOFA is not a supplement and is not available as an obesity medication.
Laboratory suppliers may sell research-grade TOFA for experimental use. That material is not a pharmaceutical weight-loss product and is not intended for human consumption.
What Exactly Did the New TOFA Study Test?
The paper was much broader than a single weight-loss experiment. The investigators conducted more than 20 experiments using cell systems and several mouse models of obesity, glucose dysregulation, and metabolic fatty-liver disease.
The central obesity experiments used male C57BL/6J mice fed a diet containing 60% of calories from fat long enough to develop diet-induced obesity. In one key four-week experiment, the mice received oral TOFA at 125 mg/kg twice daily for the first week, followed by 62.5 mg/kg twice daily for the remaining three weeks.
| Study Feature | What Researchers Used | Why It Matters |
|---|---|---|
| Species | Mice | Animal studies can reveal mechanisms without reliably predicting human efficacy or safety. |
| Sex | Male mice only | The study does not establish that female animals would respond the same way. |
| Obesity model | High-fat-diet-induced obesity | A useful metabolic model, but not equivalent to the biological and behavioral diversity of human obesity. |
| Treatment duration | Generally several weeks | Human obesity treatment may continue for years, making chronic safety a much larger question. |
| Body composition | EchoMRI | Researchers could distinguish fat-mass changes from lean-mass changes instead of relying on body weight alone. |
| Energy metabolism | Metabolic cages and indirect calorimetry | Food intake, activity, temperature, oxygen use, and energy expenditure could be measured under controlled conditions. |
The researchers also used MASH-related mouse models to examine liver fat, inflammation, fibrosis, glucose control, insulin signaling, serum lipids, and liver triglycerides.
What Did the TOFA-Treated Mice Actually Lose?
This is the part of the study I think deserves the most attention.
In the main diet-induced obesity experiment, TOFA-treated mice ended up roughly 18% lighter than the comparison trajectory over about four weeks. Food intake did not significantly differ between the TOFA and control animals.
EchoMRI body-composition analysis showed a highly significant reduction in fat mass. The lean-mass comparison did not cross the conventional threshold for statistical significance. The reported P value for lean mass was 0.053.
That does not mean the study proved that TOFA preserves every gram of skeletal muscle. EchoMRI measures lean mass, which is not identical to skeletal muscle tissue. The experiment was also short and involved a small number of male mice.
The useful headline is not simply “18% weight loss.” It is the composition of the change.
The animals became lighter primarily because fat mass fell, while measured lean mass was largely preserved over the short experimental period. Whether humans would show the same partitioning is completely unknown.
That distinction is exactly why I have argued throughout our body-composition content that weight loss and improved body composition are not automatically the same outcome. Our InBody and DEXA guide explains why fat mass, lean tissue, strength, waist measurements, and repeated trends can tell us more than scale weight alone.
How Did the Mice Lose Fat Without Eating Less?
The researchers' working explanation is a combination of higher energy expenditure and altered lipid metabolism.
After one week of treatment in a separate experiment, TOFA-treated obese mice already showed lower body mass and fat mass without a significant lean-mass difference. Metabolic-cage testing then showed higher whole-body energy expenditure under key experimental conditions.
UC Berkeley reported that the increase reached about 18% under some conditions. Importantly, the difference was not explained by greater physical activity. The mice were not simply moving more.
The researchers also did not find a meaningful increase in body temperature. That matters because pharmacologically increasing energy expenditure has a dangerous historical precedent: some compounds have increased metabolic rate by generating excessive heat. TOFA did not produce that pattern in these mouse experiments.
The energy-expenditure effect also persisted under thermoneutral housing conditions, where mice do not need to generate as much heat to maintain body temperature. That makes a simple “TOFA just turns on brown fat” explanation less convincing. The liver, skeletal muscle, heart, and other metabolically active tissues may contribute, but the precise tissue-level contribution is not yet settled.
TOFA and GLP-1 Drugs Appear to Pull Different Levers
The simplest educational comparison is the energy-balance equation, as long as we do not oversimplify either class.
| Approach | Primary Lever | Important Nuance |
|---|---|---|
| Semaglutide / tirzepatide | Primarily reduce energy intake through appetite, satiety, and related incretin effects. | These medications also affect glucose regulation, gastric emptying, insulin signaling, and other metabolic pathways. “They make you eat less” is directionally useful but biologically incomplete. |
| TOFA research | Appears to increase energy expenditure and alter lipid synthesis/oxidation without reducing food intake in mice. | This is a proposed preclinical mechanism. No human obesity study has confirmed the effect. |
Incretin medications have been enormously successful partly because they can make a sustained calorie deficit easier to achieve. TOFA is scientifically interesting because the mouse data suggest a compound might influence the energy-expenditure and lipid-metabolism side instead.
That difference is also why the researchers are studying TOFA as a potentially complementary mechanism rather than assuming it should replace GLP-1 or GIP/GLP-1 medications.
Why the Lean-Mass Finding Deserves More Attention Than the Scale
Substantial weight loss rarely consists of pure adipose tissue. Calorie restriction, bariatric surgery, and anti-obesity medications can all reduce fat mass while also producing some change in lean or fat-free mass.
Lean mass is not synonymous with skeletal muscle. It includes substantial water and other non-fat tissue. That distinction is particularly important when discussing semaglutide muscle loss or tirzepatide muscle preservation, because many headlines use “muscle” when the study actually measured DXA lean mass.
For example, the STEP 1 semaglutide body-composition substudy found large reductions in total and visceral fat along with an absolute reduction in lean mass. In the SURMOUNT-1 DXA substudy, approximately 75% of tirzepatide-associated weight loss was fat mass and about 25% was lean mass. A newer 2026 systematic review concluded that the available comparative evidence is still too heterogeneous and limited to make definitive claims about preferential fat loss or skeletal-muscle preservation across GLP-1-based therapies.
So I would not use TOFA's mouse data to declare that current incretin drugs “waste muscle.” That would be an unfair cross-species comparison. I would use it to ask a better question: Can future obesity treatments improve the composition and functional quality of weight loss?
No pharmaceutical, no matter how ingenious, can replace the need for activity, proper nutrition and proactive behaviors that lead to positive outcomes. GLP-1, and the promising findings about TOFA should never be a replacement for constructive personal behaviors. These drugs can mask symptoms of terrible lifestyle choices that may have outstanding long-term consequences if ignored. These drugs should be used as tools, not as an excuse to be reckless about one's wellness and abandon personal responsibility.
For the practical side of preserving strength and useful lean tissue during medication-assisted weight loss, see Why GLP-1 Users Shouldn’t Follow Generic Fitness Plans, our Proteinmaxxing guide, and Longevity-Focused Training.
What Happened When TOFA Was Combined With Semaglutide or Tirzepatide?
This was one of the paper's most provocative experiments.
Male mice with diet-induced obesity received vehicle, TOFA, semaglutide, tirzepatide, TOFA plus semaglutide, or TOFA plus tirzepatide for 24 days. TOFA was given at 200 mg/kg/day, while semaglutide and tirzepatide were each given at 0.5 nmol/kg/day in this experiment.
The combination groups produced stronger effects across body weight and several metabolic measurements than the individual treatments. The paper describes the interaction as more than additive for obesity, dyslipidemia, and insulin resistance. The researchers measured body composition, glucose tolerance, fasting insulin, serum triglycerides, and liver triglycerides.
The TOFA-plus-tirzepatide response became unusually aggressive.
Because those mice were experiencing severe, rapid-onset weight loss, the researchers reduced both TOFA and tirzepatide to half concentrations by day 10 for maintenance. That observation should increase caution, not excitement about recreating the combination outside a laboratory.
The concept is straightforward: if an incretin medication reduces energy intake while another agent increases energy expenditure or changes fat metabolism, the mechanisms could theoretically complement one another.
But there is an enormous gap between a mechanistic mouse experiment and a viable human combination therapy. Human researchers would have to establish the safety, pharmacokinetics, dose-response relationship, and adverse-event profile of TOFA or a related development compound before a meaningful combination trial could even be considered.
For context on the human evidence we already have, see Tirzepatide vs. Semaglutide: What the Head-to-Head Weight-Loss Evidence Actually Shows.
What Happened After TOFA or Semaglutide Was Stopped?
The researchers also performed a small follow-up experiment specifically examining post-treatment weight.
Male mice were treated for three weeks with vehicle, TOFA, or semaglutide and then monitored for another five weeks after treatment ended. The TOFA-treated mice maintained more of the lower body-weight trajectory after withdrawal, while the semaglutide-treated animals increased food intake and regained weight more quickly.
That observation is intriguing because human withdrawal studies with semaglutide and tirzepatide also demonstrate substantial weight recurrence in many participants when effective obesity pharmacotherapy is stopped.
This does not prove TOFA would prevent human weight regain.
The post-treatment experiment involved only about five mice per group. Five weeks of mouse follow-up cannot establish durable human weight maintenance or prove that the underlying biology of obesity has been permanently changed.
TOFA Also Improved Glucose, Insulin, and Fatty-Liver Markers in Mice
The paper goes well beyond body weight.
In the main obesity model, TOFA improved glucose tolerance and markedly lowered fasting insulin. Liver triglycerides, serum triglycerides, and several cholesterol fractions also decreased.
The researchers separately tested TOFA in mouse models designed to reproduce features of metabolic dysfunction-associated steatohepatitis, or MASH. Treatment reduced liver triglycerides, hepatic steatosis, inflammatory gene expression, collagen-related markers, and histologic indicators of liver injury and fibrosis.
That is relevant because ACC inhibition has long been attractive for fatty-liver disease. Blocking ACC can reduce de novo lipogenesis—the process of making new fat in the liver.
But there is a known problem with the drug class: human trials of other ACC inhibitors have frequently increased triglycerides in the bloodstream.
The Biggest Question Is Not “Does It Burn Fat?” It Is “Can This Be Done Safely?”
Increasing energy expenditure pharmacologically is an attractive idea with a difficult history. The benefit is obvious: in theory, someone could expend more energy without relying entirely on appetite suppression. The danger is equally obvious: cellular energy metabolism is fundamental biology, and changing it throughout the body can create consequences far outside adipose tissue.
The short TOFA experiments did not show hyperthermia, and the researchers reported oral bioavailability and short-term tolerability in their animal work. They also did not see the triglyceride increase that has troubled other ACC inhibitors.
That triglyceride result is encouraging, but it is not proof that TOFA has solved the ACC-inhibitor safety problem.
A 2025 systematic review and meta-analysis of six randomized human trials involving 655 participants found that ACC inhibitors reduced liver fat but increased the risk of hypertriglyceridemia more than tenfold relative to control treatment. Firsocostat trials have documented the same issue directly.
The Berkeley team believes TOFA's added PPARα/δ activity may help the body handle lipids differently enough to prevent that rise. That hypothesis now needs to survive human testing.
Mouse triglycerides cannot clear a human drug class.
Human trials would need to determine what systemic dose is safe, how long-term ACC1/2 inhibition plus PPARα/δ activation affects the liver, heart, skeletal muscle, lipoproteins, reproductive biology, and other tissues, and whether unexpected toxicities emerge with chronic use.
Has anything related to TOFA ever been used in humans?
There is an important technical nuance. An older topical acne drug candidate called olumacostat glasaretil is a prodrug that is converted to TOFA in tissue and was studied in human acne trials. A phase IIa trial evaluated a topical 7.5% gel for 12 weeks.
That history is worth knowing, but it does not establish the systemic safety of orally administered TOFA for obesity. A topical dermatology prodrug, applied to the skin for a different disease and exposure pattern, cannot answer the pharmacology questions required for chronic metabolic treatment.
The Limitations Are Central to the Story
| Limitation | Why It Changes Interpretation |
|---|---|
| Mice, not humans | Drug metabolism, energy expenditure, adipose biology, dosing, and toxicity do not translate directly between species. |
| Male animals only | The obesity study does not establish efficacy or safety in female animals, much less women. |
| Short treatment periods | Several weeks cannot model years of chronic obesity treatment. |
| Small experimental groups | Many treatment arms included roughly 4–10 animals. These studies are designed for mechanistic discovery, not clinical certainty. |
| High experimental doses | Mouse mg/kg dosing cannot be converted directly into a safe or effective human prescription. |
| Lean mass is not muscle | The strong body-composition signal still does not prove preservation of skeletal muscle protein, strength, or physical function. |
| No human obesity data | There are no human obesity efficacy results, systemic dose-finding studies, or long-term metabolic safety outcomes for TOFA. |
| Commercial interests | Several investigators co-founded ReRx Therapeutics and hold equity or patent interests related to the discovery. |
The primary paper discloses that Anders Näär, Justin Lee, and Prabha Ibrahim are co-founders of ReRx Therapeutics, which is developing drugs related to the work. Näär, Lee, and Chi Zhu are named inventors on pending patent applications covering therapeutic uses of TOFA in metabolic disease.
That does not invalidate the experiments. Academic discoveries are frequently licensed and developed commercially. It does make independent replication and transparent later-stage trials particularly important.
How Far Is TOFA From Becoming a Human Weight-Loss Treatment?
Very far.
The published evidence is a preclinical proof of concept. Chemical & Engineering News reports that the team behind ReRx Therapeutics has completed dose-ranging toxicity studies in rats and plans additional work in rhesus macaques using a development candidate called ReRx-001.
That is still preclinical development. Before a new systemic obesity treatment could reach patients, a development program would generally have to move through several major stages.
Broader Preclinical Safety
Researchers need toxicology, pharmacokinetic, reproductive, organ-specific, and dose-ranging data sufficient to justify human exposure.
First-in-Human Studies
If regulators allow clinical testing, early trials would first determine how the development compound behaves in people and what doses can be administered safely.
Human Proof of Concept
Researchers would then need evidence that the mechanism actually changes human energy expenditure, fat mass, glucose control, liver health, or body weight in a clinically useful way.
Large, Longer-Term Trials
A viable obesity medication would ultimately need adequately powered trials establishing efficacy, safety, durability, adverse events, and clinically meaningful outcomes across diverse adults.
Many promising preclinical compounds never survive that path. TOFA could fail because of toxicity, inadequate human efficacy, poor pharmacokinetics, off-target effects, manufacturing problems, or because a better related molecule replaces it.
The biology can still matter even if TOFA itself never becomes a medication. Demonstrating that fat loss can potentially be shifted by coordinating lipid synthesis and energy expenditure could influence how future obesity drugs are designed.
What Should Someone Trying to Lose Fat Take From This Research Today?
Not a new supplement. Not a reason to buy research-grade TOFA. Not a reason to stop or alter a prescribed GLP-1 medication.
The practical lesson is much simpler: the quality of weight loss matters.
A lower scale weight can be a valuable health outcome when excess body fat is reduced. But I also want to know what happened to strength, physical function, training capacity, nutrition quality, and daily activity during the process.
We already have human evidence showing that resistance training can improve the composition of diet-induced weight loss. A 2025 systematic review and meta-analysis of randomized trials found that adding resistance exercise to dietary weight loss helped protect fat-free mass, increased fat-mass loss, and substantially improved muscular strength compared with diet alone.
That is also why the 2025 multi-society GLP-1 nutrition advisory emphasizes resistance training, appropriate diet, muscle strength, physical function, and body-composition awareness during obesity pharmacotherapy.
Our own 2026 GLP-1 exercise article makes the same point from another direction: losing weight does not automatically make someone stronger, fitter, or more active.
I would welcome future obesity treatments that make fat loss more selective. Until those options exist in humans, we should not ignore the tools we already have. Progressive strength training, adequate nutrition, appropriate protein, sensible recovery, and a well-managed rate of loss can improve the quality of a weight-loss phase today.
Frequently Asked Questions About TOFA and Weight Loss
What is TOFA?
TOFA is 5-tetradecyloxy-2-furoic acid, a research compound known to inhibit ACC1 and ACC2. The 2026 Science Advances study also found that it partially activates PPARα and PPARδ, receptors involved in lipid metabolism and energy-expenditure pathways.
Did TOFA cause weight loss without reducing appetite?
In obese male mice, food intake did not significantly decrease while body weight and fat mass fell. There are no human obesity data showing the same effect.
How much weight did the mice lose?
In a key diet-induced obesity experiment, TOFA produced roughly an 18% body-weight difference over about four weeks. That short-term mouse result should not be extrapolated to human weight loss.
Did the mice lose muscle?
EchoMRI showed a significant reduction in fat mass without a statistically significant reduction in lean mass in the main obesity experiment. Lean mass is not identical to skeletal muscle, and muscle strength or human physical function were not being measured.
How did TOFA increase fat loss if the mice did not eat less?
The researchers measured higher energy expenditure and found that TOFA both inhibits ACC1/2 pathways involved in lipid synthesis and activates PPARα/δ pathways involved in fatty-acid use and energy metabolism.
Is TOFA better than semaglutide or tirzepatide?
No scientific comparison supports that conclusion. Semaglutide and tirzepatide have large human clinical-trial programs and regulatory approvals. TOFA currently has preclinical obesity data in mice.
What happened when TOFA was combined with semaglutide?
In mice, the combination produced stronger body-weight and metabolic effects than either treatment alone across several measurements. It does not establish a safe or effective human combination.
What happened when TOFA was combined with tirzepatide?
The combination produced such rapid weight loss in the mouse experiment that researchers reduced both compounds to half concentrations by day 10. This is a preclinical safety and dosing signal, not a human treatment recommendation.
Could TOFA eventually complement GLP-1 medications?
That is one of the hypotheses raised by the research because the mechanisms appear to act on different sides of energy balance. Whether the approach is safe or useful in humans is completely unknown.
Is TOFA FDA approved?
No. TOFA is not FDA approved as an obesity medication or for systemic metabolic treatment.
Can I buy TOFA for weight loss?
No approved pharmaceutical TOFA weight-loss product exists. Research-grade TOFA sold by chemical suppliers is intended for laboratory use and should not be consumed.
Has TOFA ever been tested in humans?
There are no human systemic obesity trials of TOFA. An older topical prodrug called olumacostat glasaretil, which converts to TOFA in tissue, was studied for acne. That dermatology research does not establish oral or systemic TOFA safety or efficacy for obesity.
Why are researchers concerned about triglycerides?
Other ACC inhibitors have increased circulating triglycerides in human trials. TOFA did not show that pattern in the short mouse experiments, possibly because of its additional PPARα/δ activity, but human testing is required to know whether that difference is clinically real.
What can I do now to preserve muscle during weight loss?
For generally healthy adults, progressive resistance training, adequate protein and total nutrition, appropriate recovery, and monitoring strength and function are practical evidence-based priorities. Medical conditions and obesity medications can change individual needs.
Lose Weight Without Losing Sight of What Your Body Can Do.
Future obesity treatments may become better at separating fat loss from lean-tissue loss. The principles available today still matter: progressive resistance training, adequate nutrition, protein, recovery, cardiovascular fitness, and habits that protect physical function while body weight changes.
Evidence and Supporting Documentation
- Lee JY, et al. A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders. Science Advances. 2026;12(34):eaed3119.
- Original Science Advances article DOI: 10.1126/sciadv.aed3119.
- University of California, Berkeley. Research summary and investigator context for the 2026 TOFA study.
- Hasanatuludhhiyah N, et al. Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceuticals. 2025.
- Lawitz EJ, et al. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clinical Gastroenterology and Hepatology. 2023.
- Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. 2025.
- Menezes MLL, et al. Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework. 2026.
- Binmahfoz A, et al. Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: systematic review and meta-analysis. 2025.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: multi-society joint advisory. Obesity. 2025.
- Bissonnette R, et al. Olumacostat glasaretil, a topical TOFA prodrug, in the treatment of acne vulgaris: phase IIa randomized study. Journal of the American Academy of Dermatology. 2017.
- Chemical & Engineering News. Development context, preclinical safety work, and ReRx-001 reporting. August 2026.
Reviewed by: Michael S. Parker — 12 professional certifications across NASM, NESTA, Functional Movement Systems, and the Spencer Institute, plus 25+ years of coaching experience. View his full certification list. Medical and research disclaimer: TOFA is an experimental research compound and is not approved as a human obesity treatment. The obesity findings discussed here are preclinical mouse data and do not establish human systemic safety, efficacy, dosing, or long-term outcomes. Do not purchase or consume research-grade TOFA. People considering or currently using prescription obesity medication should make medication decisions with an appropriately licensed healthcare professional. Forge provides fitness, nutrition, and habit coaching and does not prescribe or manage medication.
